Prescription and Utilization of Low Molecular Weight Heparin in Usual Medical Practice for the Curative Treatment of Venous Thromboembolism in Patients With Cancer

LEO Pharma

Status: Completed

Conditions: Venous Thromboembolism

Study type: Observational

Funder types: Industry

Identifiers

NCT01803022

Tropique

Details and patient eligibility

About

The study purpose is to document the prescription and the use of Low Molecular Weight Heparin in usual medical practice in patients with cancer and established Venous Thromboembolism. This study also aims at gathering epidemiological data on the Low Molecular Weight Heparin therapy of Venous Thromboembolism in patients with cancer.

Enrollment: 419 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects must provide informed consent
• Men or women aged 18 years or more
• Ongoing cancer disease recent diagnosis of veinous thromboembolism treatment with Low Molecular Weight Heparin before entry into the study

Exclusion criteria

• Contraindication to the use of Low Molecular Weight Heparin

Trial design

419 participants in 1 patient group

Low Molecular Weight Heparin